Report
EUR 13.14 For Business Accounts Only

GUARDANT HEALTH presents increased market risk and shows a lower rating of Slightly Negative

The independent financial analyst theScreener just requalified the risk of GUARDANT HEALTH (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives a new star(s) and now shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and can be qualified as risky. theScreener considers that these elements lead to an overall rating downgrade to Slightly Negative while the title remains exposed to strong pressure. As of the analysis date January 4, 2022, the closing price was USD 97.98 and its target price was estimated at USD 73.07.
Underlying
Guardant Health

Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. The company is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. The company's Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, the company is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch